|
|
Article: BEMA Buprenorphine to Proceed to Phase 2 Following Favorable Initial Study Results.
- Article from:
- Business Wire
- Article date:
- March 18, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioDelivery Sciences' Second Product Using the BEMA Drug Delivery Technology to Enter Phase 2 in June
RALEIGH, N.C. -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced preliminary results from a Phase 1 study assessing two new formulations of the opioid analgesic buprenorphine utilizing the company's proprietary BEMA([TM])drug delivery technology. The study was performed to select the optimal formulation for Phase 2 clinical development of the product candidate, known as BEMA([TM]) Buprenorphine.
Fourteen healthy volunteers participated in this randomized, blinded, cross-over study which compared two formulations of BEMA Buprenorphine ...